[{"data":1,"prerenderedAt":270},["ShallowReactive",2],{"$f2jkxqyxlc1dbz":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":23,"top_modalities":58,"top_diseases":88,"top_companies":115,"key_results":144,"trends":235,"previous_editions":244,"comparison":248,"highlighted_classes":266},1,"esmo-2026","ESMO","esmo","ESMO Congress 2026",2026,"Oncology","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},4411,2184,375,{"Phase 1":17,"Phase 1\u002F2":18,"Phase 2":19,"Phase 4":20,"Phase 2\u002F3":21,"Phase 3":22},217,125,461,3,11,309,[24,28,32,36,39,43,46,49,52,55],{"name":25,"count":26,"share":27},"PDCD1",451,21,{"name":29,"count":30,"share":31},"ERBB2",146,7,{"name":33,"count":34,"share":35},"CD274",118,5,{"name":37,"count":38,"share":35},"EGFR",102,{"name":40,"count":41,"share":42},"VEGFR2",88,4,{"name":44,"count":45,"share":42},"TUBB",84,{"name":47,"count":48,"share":42},"TS",82,{"name":50,"count":51,"share":42},"VEGFR4",79,{"name":53,"count":54,"share":20},"CTLA-4",68,{"name":56,"count":57,"share":20},"TOP1",66,[59,63,67,71,75,78,81,85],{"name":60,"count":61,"share":62},"Small molecules",1127,52,{"name":64,"count":65,"share":66},"Monoclonal antibodies",827,38,{"name":68,"count":69,"share":70},"Antibody-drug conjugates",297,14,{"name":72,"count":73,"share":74},"Bispecific antibodies",165,8,{"name":76,"count":77,"share":20},"Radiopharmaceuticals",69,{"name":79,"count":80,"share":20},"Non-antibody therapeutic proteins",56,{"name":82,"count":83,"share":84},"Peptides",36,2,{"name":86,"count":87,"share":84},"Cell therapies",33,[89,92,95,98,101,103,106,108,110,113],{"name":90,"count":91,"share":70},"non-small cell lung cancer (NSCLC)",305,{"name":93,"count":94,"share":70},"breast cancer",302,{"name":96,"count":97,"share":31},"colorectal cancer (CRC)",152,{"name":99,"count":100,"share":35},"melanoma",103,{"name":102,"count":100,"share":35},"prostate cancer (PCa)",{"name":104,"count":105,"share":42},"ovarian cancer",97,{"name":107,"count":105,"share":42},"triple-negative breast cancer (TNBC)",{"name":109,"count":51,"share":42},"pancreatic adenocarcinoma (PDAC)",{"name":111,"count":112,"share":20},"pancreatic cancer (PC)",72,{"name":114,"count":77,"share":20},"gastric cancer (GC)",[116,119,122,125,128,131,134,137,139,141],{"name":117,"count":118,"share":74},"Merck",174,{"name":120,"count":121,"share":74},"Bristol Myers Squibb",173,{"name":123,"count":124,"share":35},"AstraZeneca",111,{"name":126,"count":127,"share":35},"Pfizer",100,{"name":129,"count":130,"share":42},"Genentech",92,{"name":132,"count":133,"share":20},"Daiichi Sankyo",63,{"name":135,"count":136,"share":20},"Eli Lilly",59,{"name":138,"count":80,"share":20},"Amgen",{"name":140,"count":62,"share":84},"Novartis",{"name":142,"count":143,"share":84},"Astellas Pharma",47,[145,154,163,170,177,185,192,199,207,214,222,229],{"title":146,"drug":147,"company":150,"phase":151,"disease":93,"finding":152,"url":153},"APEX-Breast01: TQB2102 versus chemotherapy in HER2-low recurrent or metastatic breast cancer (r\u002Fm BC) - Results from a randomized phase 3 study",{"name":148,"slug":149},"TQB2102","tqb2102","Chia Tai Tianqing Pharmaceutical Group","Phase 3","The PFS were significantly improved in the TQB2102 group than in the TPC group both in HR+\u002FHER2-low pts (median, 16.4 mo vs 5.5 mo; HR, 0.29 [95% CI 0.22-0.39]; p\u003C0.0001 ) and in all HER2-low pts (median, 16.4 mo vs 5.5 mo; HR, 0.29 [95% CI 0.22-0.38]; p\u003C0.0001 ).","https:\u002F\u002Fcslide.ctimeetingtech.com\u002Fesmo2026\u002Fattendee\u002Fconfcal\u002Fshow\u002Fsession\u002F240#LBA27",{"title":155,"drug":156,"company":159,"phase":151,"disease":160,"finding":161,"url":162},"Arcotatug tavatecan (IBI343\u002FTAK-921) versus treatment of physician’s choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G\u002FGEJA): First interim analysis of the randomized, open-label, phase 3, G-HOPE-001 study",{"name":157,"slug":158},"arcotatug tavatecan","arcotatug-tavatecan","Innovent Biologics","gastric adenocarcinoma","With 34.8% of events, median OS was 9.9 months vs 7.4 months (HR: 0.63 [95% CI: 0.45-0.89]).","https:\u002F\u002Fcslide.ctimeetingtech.com\u002Fesmo2026\u002Fattendee\u002Fconfcal\u002Fshow\u002Fsession\u002F241#LBA77",{"title":164,"drug":165,"company":167,"phase":151,"disease":102,"finding":168,"url":169},"Perioperative apalutamide (APA) plus androgen-deprivation therapy (ADT) with radical prostatectomy plus pelvic lymph node dissection (RP + PLND) vs RP + PLND alone in patients (pts) with high-risk localized or locally advanced prostate cancer (HR LPC\u002FLAPC): PROTEUS substudy",{"name":166,"slug":166},"apalutamide",null,"The primary end point was met: median EFS not reached (APA + ADT) vs 19.1 mo (RP alone); HR 0.38 (95% CI 0.26-0.55; p\u003C0.0001).","https:\u002F\u002Fcslide.ctimeetingtech.com\u002Fesmo2026\u002Fattendee\u002Fconfcal\u002Fshow\u002Fsession\u002F260#LBA53",{"title":171,"drug":172,"company":174,"phase":151,"disease":90,"finding":175,"url":176},"Savolitinib or placebo combined with osimertinib in treatment-naïve advanced NSCLC with EGFR mutation and MET overexpression: Results from the phase 3 SANOVO study",{"name":173,"slug":173},"savolitinib","HUTCHMED","Savo+osi significantly prolonged INV-assessed PFS vs. placebo+osi in both MET IHC 3+ (24.8 vs. 11.1 mo; HR 0.45; 95% CI 0.31 to 0.66; P\u003C0.0001) and ITT populations (24.9 vs. 13.8 mo; HR 0.56; 95% CI, 0.43 to 0.74; P\u003C0.0001).","https:\u002F\u002Fcslide.ctimeetingtech.com\u002Fesmo2026\u002Fattendee\u002Fconfcal\u002Fshow\u002Fsession\u002F283#LBA69",{"title":178,"drug":179,"company":167,"phase":151,"disease":182,"finding":183,"url":184},"Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial",{"name":180,"slug":181},"enfortumab vedotin","enfortumab-vedotin","muscle-invasive bladder carcinoma (MIBC)","D+EV showed significant improvements in EFS (HR 0.51 [95% CI, 0.38–0.67], P\u003C0.0001; 24-mo rate 64% vs 45%) and OS (HR 0.58 [95% CI, 0.40–0.83], P=0.0027; 24-mo rate 78% vs 69%) vs control.","https:\u002F\u002Fcslide.ctimeetingtech.com\u002Fesmo2026\u002Fattendee\u002Fconfcal\u002Fshow\u002Fsession\u002F346#LBA2",{"title":186,"drug":187,"company":138,"phase":151,"disease":189,"finding":190,"url":191},"Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial",{"name":188,"slug":188},"tarlatamab","small cell lung cancer (SCLC)","With median (m) follow-up time of 15.9 and 16.1 months (mo), respectively, tarlatamab + durva significantly improved OS (HR: 0.42; 95% CI 0.32, 0.54; P \u003C0.001; mOS: 21.1 [95% CI, 20.8 to NE] vs 12.7 mo [95% CI, 11.2 to 14.8]).","https:\u002F\u002Fcslide.ctimeetingtech.com\u002Fesmo2026\u002Fattendee\u002Fconfcal\u002Fshow\u002Fsession\u002F346#LBA3",{"title":193,"drug":194,"company":196,"phase":151,"disease":102,"finding":197,"url":198},"Darolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 trial (DASL-HiCaP; ANZUP1801)",{"name":195,"slug":195},"darolutamide","Bayer","MFS-CI was longer amongst those assigned darolutamide vs placebo: 4-year MFS-CI 95% vs 88%, hazard ratio 0.42 (95% CI 0.27 to 0.66), 27 vs 63 events, p=0.0001.","https:\u002F\u002Fcslide.ctimeetingtech.com\u002Fesmo2026\u002Fattendee\u002Fconfcal\u002Fshow\u002Fsession\u002F346#LBA4",{"title":200,"drug":201,"company":117,"phase":151,"disease":204,"finding":205,"url":206},"Sacituzumab tirumotecan in previously treated advanced or recurrent endometrial cancer: Results from the phase 3 TroFuse-005\u002FENGOT-en23\u002FGOG-3095 study",{"name":202,"slug":203},"sacituzumab tirumotecan","sacituzumab-tirumotecan","endometrial cancer (EC)","Statistically significant improvements in PFS (HR, 0.59 [95% CI, 0.50–0.70]; P\u003C0.0001) and OS (HR, 0.68 [95% CI, 0.55–0.84]; P=0.0001) were observed with sac-TMT vs TPC; ORR was also significantly improved vs TPC.","https:\u002F\u002Fcslide.ctimeetingtech.com\u002Fesmo2026\u002Fattendee\u002Fconfcal\u002Fshow\u002Fsession\u002F347#LBA11",{"title":208,"drug":209,"company":211,"phase":151,"disease":90,"finding":212,"url":213},"Krascendo 1: Efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC",{"name":210,"slug":210},"divarasib","Roche","A statistically significant benefit in PFS (HR: 0.58; 95% CI: 0.44–0.76) and OS (HR: 0.56; 95% CI: 0.41–0.78) was observed for the diva vs control arm.","https:\u002F\u002Fcslide.ctimeetingtech.com\u002Fesmo2026\u002Fattendee\u002Fconfcal\u002Fshow\u002Fsession\u002F348#LBA5",{"title":215,"drug":216,"company":218,"phase":151,"disease":219,"finding":220,"url":221},"RINGSIDE phase 3 study of varegacestat in desmoid tumors: Primary results and T2-weighted signal intensity changes",{"name":217,"slug":217},"varegacestat","Immunome","aggressive fibromatosis (AF)","VAR significantly improved PFS vs PBO (HR: 0.16 [95% CI: 0.07, 0.38]; P\u003C0.0001).","https:\u002F\u002Fcslide.ctimeetingtech.com\u002Fesmo2026\u002Fattendee\u002Fconfcal_1\u002Fpresentation\u002Flist?q=3755P#3755P",{"title":223,"drug":224,"company":167,"phase":151,"disease":93,"finding":227,"url":228},"PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA\u002FM) hormone receptor-positive\u002FHER2-negative (HR+\u002FHER2-) breast cancer (BC)",{"name":225,"slug":226},"izalontamab brengitecan","izalontamab-brengitecan","Iza-bren significantly improved PFS by BICR vs TPC; mPFS was 8.18 mo (95% CI, 6.93-8.58) vs 4.01 mo (95% CI, 2.92-4.30) (HR, 0.41; 95% CI, 0.33-0.53; P\u003C0.0001).","https:\u002F\u002Fcslide.ctimeetingtech.com\u002Fesmo2026\u002Fattendee\u002Fconfcal\u002Fshow\u002Fsession\u002F240#LBA50",{"title":230,"drug":231,"company":126,"phase":151,"disease":99,"finding":233,"url":234},"STARBOARD phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma",{"name":232,"slug":232},"encorafenib","Both primary and key secondary EPs were met; confirmed ORR was 70.0% (triplet) vs 32.7% (control); median PFS was 33.0 vs 3.4 mo, respectively, and risk of disease progression or death was reduced by 67% for triplet vs control.","https:\u002F\u002Fcslide.ctimeetingtech.com\u002Fesmo2026\u002Fattendee\u002Fconfcal\u002Fshow\u002Fsession\u002F250#2071O",{"summary":236,"bullets":238},[237],"Monoclonal antibodies accounted for 38% of drug-linked abstracts, up from 33% in 2025. Small molecules, the most frequent modality, accounted for 52% of drug-linked abstracts, up from 47% in 2025. TOP1 (3%) was new to the top targets compared with 2025.",[239,240,241,242,243],"PDCD1 was the most frequent target (21% of drug-linked abstracts).","Non-small cell lung cancer (NSCLC) was the most frequent disease (14%).","Merck had the largest company share (8%).","Antibody-drug conjugates accounted for 14% of drug-linked abstracts, up from 11% in 2025.","Bispecific antibodies accounted for 8% of drug-linked abstracts, up from 5% in 2025.",[245],{"year":246,"abstracts":247},2025,3365,{"previous_year":246,"abstracts":167,"targets":249,"modalities":257,"new_in_top_targets":264,"new_in_top_modalities":265},[250,254],{"name":25,"count":26,"share":27,"previous_count":251,"previous_share":252,"direction":253},295,19,"rose",{"name":33,"count":34,"share":35,"previous_count":255,"previous_share":74,"direction":256},120,"fell",[258,260,262],{"name":64,"count":65,"share":66,"previous_count":259,"previous_share":87,"direction":253},512,{"name":60,"count":61,"share":62,"previous_count":261,"previous_share":143,"direction":253},738,{"name":68,"count":69,"share":70,"previous_count":263,"previous_share":21,"direction":253},164,[56],[],[267,268],{"name":68,"count":69,"share":70,"previous_count":263,"previous_share":21,"direction":253},{"name":72,"count":73,"share":74,"previous_count":269,"previous_share":35,"direction":253},74,1793970603093]